Table 4.
Associations Between Clinicopathological Parameters and DFS in HER2-Positive Breast Cancer
| Variables | Univariate Analysis | Multivariate Analysis | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) | ||||
| ≤ 35 | 1 | / | ||
| > 35 | 1.50 (0.17–12.97) | 0.711 | / | / |
| Tumor stage | ||||
| pT1 | 1 | 1 | ||
| pT2-4 | 6.67 (1.51–29.41) | 0.005 | 6.00 (1.57–22.82) | 0.009 |
| Tumor differentiation | ||||
| G1-2 | 1 | 1 | ||
| G3 | 3.24 (1.36–7.69) | 0.006 | 3.60 (1.33–9.73) | 0.012 |
| Lymph node involvement | ||||
| pN0 | 1 | 1 | ||
| pN1-3 | 3.14 (1.25–7.94) | 0.012 | 6.76 (2.56–17.84) | <0.001 |
| HR status | ||||
| Positive | 1 | 1 | ||
| Negative | 2.22 (0.91–5.41) | 0.076 | 3.74 (1.46–9.58) | 0.006 |
| Ki67 | ||||
| Low (≤30%) | 1 | 1 | ||
| High (>30%) | 2.30 (0.97–5.46) | 0.055 | 1.65 (0.65–4.20) | 0.295 |
| Surgery | ||||
| Mastectomy | 1 | / | ||
| Breast-conserving surgery | 1.19 (0.36–3.92) | 0.777 | / | / |
| Radiotherapy | ||||
| Yes | 1 | / | ||
| No | 1.16 (0.50–2.68) | 0.724 | / | / |
| Endocrine therapy | ||||
| Yes | 1 | / | ||
| No | 1.75 (0.74–4.17) | 0.202 | / | / |
| NLR | ||||
| ≤1.69 | 1 | 1 | ||
| >1.69 | 3.24 (1.23–8.55) | 0.014 | 0.84 (0.22–3.18) | 0.798 |
| PLR | ||||
| ≤110 | 1 | 1 | ||
| >110 | 5.52 (1.58–19.23) | 0.003 | 7.25 (1.98–26.54) | 0.003 |
| SII | ||||
| ≤442 | 1 | 1 | ||
| >442 | 6.62 (2.60–16.95) | <0.001 | 3.78 (1.10–13.08) | 0.035 |
Abbreviations: DFS, disease-free survival; HER2, human epidermal growth factor receptor 2; HR, hazard ratio; CI, confidence interval; T, tumor; G, grade; N lymph-node; HR, hormone receptor; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index.